Growth Metrics

Regenerex Pharma (RGPX) Debt to Equity (2017 - 2024)

Regenerex Pharma (RGPX) reported Debt to Equity of -$0.05 for Q1 2024, up 61.38% year-over-year from -$0.03 in Q2 2023, and down 6178.8% on a QoQ basis from -$0.0 in Q4 2023.

Regenerex Pharma (RGPX) has 8 years of Debt to Equity data on file, last reported at -$0.05 in Q1 2024.

  • Quarterly Debt to Equity rose 61.38% year-over-year to -$0.05 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was -$0.05 (up 61.38% YoY) and the FY2024 annual result came in at -$0.05, up 61.38% from the prior year.
  • Debt to Equity slipped to -$0.05 in Q1 2024 per RGPX's latest filing, from -$0.0 in the prior quarter.
  • Across five years, Debt to Equity topped out at -$0.0 in Q4 2021 and bottomed at -$0.27 in Q1 2020.
  • The 5-year median for Debt to Equity is -$0.13 (2022), against an average of -$0.13.
  • The widest annual swing landed in 2022, when Debt to Equity plunged 114700.05%; it then jumped 99.43% in 2023.
  • Tracing RGPX's Debt to Equity over 5 years: stood at -$0.25 in 2020, then jumped by 99.96% to -$0.0 in 2021, then sank by 114700.05% to -$0.12 in 2022, then soared by 99.41% to -$0.0 in 2023, then plunged by 6178.8% to -$0.05 in 2024.
  • Per Business Quant, the three latest RGPX Debt to Equity figures stand at -$0.05 (Q1 2024), -$0.0 (Q4 2023), and -$0.0 (Q3 2023).

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 -0.05
Dec 31, 2023 0.00
Sep 30, 2023 0.00
Mar 31, 2023 -0.12
Dec 31, 2022 -0.12
Sep 30, 2022 -0.14
Jun 30, 2022 -0.13
Mar 31, 2022 -0.13
Dec 31, 2021 0.00
Sep 30, 2021 -0.15
Jun 30, 2021 -0.15
Mar 21, 2021 -0.16
Sep 30, 2020 -0.25
Jun 30, 2020 -0.27
Mar 31, 2020 -0.27
Dec 31, 2019 -0.30
Sep 30, 2019 -0.31
Jun 30, 2019 -0.33
Mar 31, 2019 -0.35
Dec 31, 2018 -0.15
Sep 30, 2018 0.00
Jun 30, 2018 0.00
Mar 31, 2018 -0.21
Dec 31, 2017 -0.15
Sep 30, 2017 -0.13
Jun 30, 2017 -0.11
Mar 31, 2017 -0.04